gastric cancer
Conditions
Interventions
icosapentaenoic acid (EPA)
Sponsors
Kyushu medical center, medical oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with clinically(radiographically/histologically/cytologically)proved adenocarcinoma of advanced gastric cancer and esophagogastric cancer (2)Patients who can intake orally (3)Patients without pretreatment for gastric cancer (4)Patients without previous chemotherapy for malignant tumor except for gastric cancer and radiation therapy to the abdominal legion (5)Patients with assessable lesion as defined by the Recist ver1.1 criteria (6)20-75 year-old at informedconsent (7)ECOG performance status(PS) 0-2 (8)Adequate bone marrow and organ function as defined as below -leukocyte count>=3000/mm3 -neutrophil count>=1500/mm3 -hemoglobin level>=8.0g/dL -platelet count>=100000/mm3 -AST and ALT=<100IU/L or AST and ALT=<200IU/L with liver metastases -total bilirubin=<1.5mg/dL -serum creatinin=<upper limit of average level in each facility, creatinin clearance>=50ml/min (10)Written informed consent obtained from patients
Exclusion criteria
Exclusion criteria: (1)Patients with active bleeding or beedingtendency (2)Patients who receive anticoagulant or antiplatelet drug (3)Patients without prior therapy with drugs or supplements contained icosapentaenoic acid (4)Patients with a history of allergy to icosapentaenoic acid (5)Patients scheduled for surgery (6)Patients scheduled for immune therapy (7)Patients with serious complication (8)Patients with immune-mediated illness (9)Patients with digestive symptom by ileus or gastrointestinal bleeding (10)Patients with symptomatic brain metastases or carcinomatous meningitis (11)Patients with massive pericardial effusion, pleural effusion or ascites *except for patients if effusions and ascites did not accumulate for more than two weeks after dranage therapy *include patients if pleurosclerosis was performed with anticancer drugs except OK-432 (12)Metachronous and synchronous double cancer (13)Bood tests positive for HBs antigen (14)Patients who receive continuous corticosteroid administration (15)Patients who receive drugs interact with S-1 or cisplatin (16)Uncontrolled psychiatry disease (17)Pregnant or lactating female and men who want to get partner pregnant (18)Judged inappropriate by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to treatment failure(TTF) of a first-line chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| rate of weight loss, alteration in nutritional status, alteration in Glasgow Prognostic score, QOL(Quality of life), adverse events, progression free survival, response rete, relative dose intense, translational research | — |
Countries
Japan
Contacts
Public ContactKotoe Takayoshi
Kyushu medical center medical oncology
Outcome results
None listed